/

Haemonetics Corporation

HAE US

HAE USHaemonetics Corporation

United States Composite

92.13

USD

+0.18

(+0.20%)

2.46EPS Dil.

36.85P/E

4.68BMarket Cap

Next Earnings

May 9

Held by Insiders

0.76%

Held by Institutions

101.08%

Short % of Float

3.87%

YTD Yield

11.43%

3Y Yield

35.28%

5Y Yield

0.35%

Capital Structure

FRC

•

in mil. unless spec.

Jun'24

Sep'24

Dec'24

ST Debt

LT Borrowings

751

749

857

LT Finance Leases

- -

Preferred Equity and Hybrid Capital

- -

Shares Outstanding

Market Capitalization

4,317

4,545

4,343

Working Capital

FRC

•

in mil. unless spec.

Jun'24

Sep'24

Dec'24

Total Current Assets

802

866

765

Cash, Cash Equivalents & STI

286

351

194

Accounts Receivable, Net

177

174

212

Inventories

289

286

304

Total Current Liabilities

237

264

262

Payables & Accruals

111

126

116

ST Debt

Deferred Revenue

- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years

5 years

1 year

Sales/Revenue/Turnover

3.06%

5.81%

17.72%

Net Income, GAAP

-53.04%

36.81%

167.44%

Free Cash Flow

97.64%

37.20%

114.47%

Total Cash Common Dividend

- -

Total Equity

1.20%

2.59%

9.21%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

2022

229

240

260

265

993

2023

261

297

305

304

1,169

2024

311

318

336

- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

2022

-0.09

0.29

0.45

0.19

0.85

2023

0.39

0.65

0.58

2.27

2024

0.81

0.49

0.62

- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

2022

- -

2023

- -

2024

- -

Company Description

CEO: Mr. Christopher A. Simon
Full Time Employees: 3,034
Sector: Healthcare
Industry: Medical Instruments & Supplies
Address: 125 Summer Street Boston MA United States 02110
IPO Date: May 10, 1991
Website: www.haemonetics.com
Business: Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot including collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

Company News

Zacks
20 days ago
Why You Should Add Haemonetics (HAE) to Your Portfolio Now
Zacks
23 days ago
HAE vs. ABT: Which Stock Is the Better Value Option?
Zacks
a month ago
Haemonetics' (HAE) New TEG 6s Cartridge Gets FDA Approval
Yahoo
a month ago
Haemonetics Corporation Completes Acquisition of Attune Medical
Zacks
a month ago
Haemonetics (HAE) Crossed Above the 200-Day Moving Average: What That Means for Investors
Yahoo
a month ago
Haemonetics (HAE) Crossed Above the 200-Day Moving Average: What That Means for Investors
Yahoo
a month ago
Does Haemonetics (NYSE:HAE) Deserve A Spot On Your Watchlist?
Zacks
2 months ago
Haemonetics (HAE) Recently Broke Out Above the 50-Day Moving Average
Yahoo
2 months ago
Haemonetics (HAE) Recently Broke Out Above the 50-Day Moving Average
Yahoo
2 months ago
Haemonetics Corporation (NYSE:HAE) Shares Could Be 35% Below Their Intrinsic Value Estimate
Zacks
2 months ago
Haemonetics (HAE) Signs Agreement to Acquire Attune Medical
Medtechdive
2 months ago
Haemonetics to buy Attune Medical for $160M
Yahoo
2 months ago
Haemonetics Announces Definitive Agreement to Acquire Attune Medical

Company Description

CEO: Mr. Christopher A. Simon
Full Time Employees: 3,034
Sector: Healthcare
Industry: Medical Instruments & Supplies
Address: 125 Summer Street Boston MA United States 02110
IPO Date: May 10, 1991
Website: www.haemonetics.com
Business: Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot including collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

Company News

Zacks
20 days ago
Why You Should Add Haemonetics (HAE) to Your Portfolio Now
Zacks
23 days ago
HAE vs. ABT: Which Stock Is the Better Value Option?
Zacks
a month ago
Haemonetics' (HAE) New TEG 6s Cartridge Gets FDA Approval
Yahoo
a month ago
Haemonetics Corporation Completes Acquisition of Attune Medical
Zacks
a month ago
Haemonetics (HAE) Crossed Above the 200-Day Moving Average: What That Means for Investors
Yahoo
a month ago
Haemonetics (HAE) Crossed Above the 200-Day Moving Average: What That Means for Investors
Yahoo
a month ago
Does Haemonetics (NYSE:HAE) Deserve A Spot On Your Watchlist?
Zacks
2 months ago
Haemonetics (HAE) Recently Broke Out Above the 50-Day Moving Average
Yahoo
2 months ago
Haemonetics (HAE) Recently Broke Out Above the 50-Day Moving Average
Yahoo
2 months ago
Haemonetics Corporation (NYSE:HAE) Shares Could Be 35% Below Their Intrinsic Value Estimate
Zacks
2 months ago
Haemonetics (HAE) Signs Agreement to Acquire Attune Medical
Medtechdive
2 months ago
Haemonetics to buy Attune Medical for $160M
Yahoo
2 months ago
Haemonetics Announces Definitive Agreement to Acquire Attune Medical